Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Equity Ratio (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Equity Ratio data on record, last reported at 0.86 in Q4 2025.

  • For Q4 2025, Equity Ratio rose 17.82% year-over-year to 0.86; the TTM value through Dec 2025 reached 0.86, up 17.82%, while the annual FY2025 figure was 0.86, 10.74% up from the prior year.
  • Equity Ratio reached 0.86 in Q4 2025 per INM's latest filing, down from 0.87 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.88 in Q3 2021 and bottomed at 0.88 in Q3 2023.
  • Average Equity Ratio over 5 years is 0.71, with a median of 0.82 recorded in 2024.
  • Peak YoY movement for Equity Ratio: plummeted 216.24% in 2023, then skyrocketed 191.44% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.73 in 2021, then increased by 15.92% to 0.85 in 2022, then dropped by 1.18% to 0.84 in 2023, then dropped by 13.15% to 0.73 in 2024, then grew by 17.82% to 0.86 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.86 in Q4 2025, 0.87 in Q3 2025, and 0.86 in Q2 2025.